MicroRNA-3194-3p and BCL9 Expression in Hepatocellular Carcinoma Tissues

Bowen Yao from Beijing University of Chemical Technology published research on miR-3194-3p in hepatocellular carcinoma. The study demonstrates that miR-3194-3p is down-regulated in HCC tissues and cell lines and inhibits metastasis and epithelial-mesenchymal transition by targeting BCL9 and decreasing Wnt/β-catenin signaling. The dataset likely contains expression levels of miR-3194-3p and BCL9 correlated with clinical outcomes.

Use Cases

• Train models to predict hepatocellular carcinoma metastasis based on miR-3194-3p expression levels.
• Analyze the correlation between BCL9 expression and adverse clinical features mentioned in the description.
• Investigate the relationship between hypoxia and microRNA down-regulation in cancer progression.
• Validate therapeutic targets for HCC by modeling the miR-3194-3p/BCL9/β-catenin pathway interaction.

Strengths

• Data is derived from primary research published in an open-access paper.
• Findings are validated through both in vitro and in vivo assays mentioned in the description.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect the specific experimental and patient cohort bias inherent to the single research paper.

Provenance

Source

Beijing University of Chemical Technology

Collection Method

Likely contains experimental data from gain- and loss-of-function assays on HCC tissues and cell lines.